

Atty Docket No.: 2300-0953
Chiron No.: 0953.001
PATENT

growth factor but lacks a sequence comprising the first 23 N-terminal amino acid residues of the mature, full-length keratinocyte growth factor, and

(b) a pharmaceutically acceptable carrier.

Please add the following new claims:

24. The keratinocyte growth factor fragment as claimed in claim 1, wherein the fragment comprises an amino acid sequence corresponding to residues 55 to 194 of Figure 1 [SEQ ID NO: 1].

25. An analog of the keratinocyte growth factor fragment as claimed in claim 24, wherein the analog has at least one conservative substitution of an amino acid with a structurally related amino acid and further wherein the analog exhibits the biological activity of the keratinocyte growth factor fragment.

26. The analog as claimed in claim 25, wherein each conservative amino acid substitution comprises an isolated amino acid replacement in the keratinocyte growth factor fragment wherein said replacement is selected from the group consisting of a leucine with an isoleucine, a leucine with a valine, an aspartic acid with a glutamic acid and a threonine with a serine.

27. An analog of the keratinocyte growth factor fragment as claimed in claim 24, wherein the analog has at least one cysteine residue substituted by another amino acid and further wherein the analog exhibits the biological activity of the keratinocyte growth factor fragment.

Atty Docket No.: 2300-0953
Chiron No.: 0953.001
PATENT

28. The analog as claimed in claim 27, wherein the cysteine residue is replaced with serine or threonine.

29. A therapeutic composition comprising:

(a) the keratinocyte growth factor fragment as claimed in claim 24, and
(b) a pharmaceutically acceptable carrier.

30. A therapeutic composition comprising:

(a) the analog as claimed in claim 25, and
(b) a pharmaceutically acceptable carrier.

31. A therapeutic composition comprising:

(a) the analog as claimed in claim 26, and
(b) a pharmaceutically acceptable carrier.

32. A therapeutic composition comprising:

(a) the analog as claimed in claim 27, and
(b) a pharmaceutically acceptable carrier.

33. A therapeutic composition comprising:

(a) the analog as claimed in claim 28, and
(b) a pharmaceutically acceptable carrier.